

Aetna Better Health®

Fax completed prior authorization request form to 877-309-8077 or submit Electronic Prior Authorization through CoverMyMeds® or SureScripts.

All requested data must be provided. <u>Incomplete forms or forms without the chart notes will be returned</u>

Pharmacy Coverage Guidelines are available at www.aetnabetterhealth.com/pennsylvania/providers/pharmacy

## Tepezza

## **Pharmacy Prior Authorization Request Form**

Do not copy for future use. Forms are updated frequently.

sis

REQUIRED: Office notes, labs and medical testing relevant to request showing medical justification are required to support diagno											iagnos	
Member Information												
Member Name (first & last):	Date of Bi	Birth:		Gender:								
					Male 🗆 Female							
Member ID:	City:			State:					Weight:			
Prescribing Provider Information												
Provider Name (first & last):	Specialty	:		NPI#			#					
Office Address:	City:			State:			ode:					
Office Contact:		Office Phone				Office Fax:						
Dispensing Pharmacy Information		l										
Pharmacy Name:			Pharmacy Phone: Pharmacy Fa				acy Fax	ix:				
Requested Medication Information												
What medication(s) has member tried and f Please specify:	ailed for this	diagnosi	s?									
Medication request is NOT for an FDA- appro compendia-supported diagnosis (circle one): Yes			ved, or Diagnosis: IC			ICD-1	D-10 Code:					
Are there any contraindications to formulary	is?						Yes		No			
If yes, please specify:												
Directions for Use:	Strength:				Dosage Form:							
	Quantity: Day Supply:			oply:	Duration of Therapy/Use:							
Turn-Around Time for Review												
☐ Standard – (24 hours)								alth,				
	or ab	ility to regain maximum function, you can ask for an expedited decision.										
	Sign	ature:	ature:									
Clinical Information												
☐ Moderate to severe Graves' disease ass	ociated with	h Thyroid	Eye Disease	(TED)								
Thyroid Eye Disease (TED) is ☐ Lid retra	n 🗆					s≥3	□ Diplopia					
associated with ONE of the							above normal					
following:			involvemer	ıt		ice and						
Was there T/F with glucocorticoids?	ППУ	es П	No Are gl	ucocortic	gend oids C/Lord		2		Yes	П	No	
(cumulative dose < 1000mg			tolerat		0103 07101 1	camorbo		_	103		110	
methylprednisolone OR equivalent)												
Was member on a high dose (> 1000mg me	thylpredniso	olone OR	equivalent) s	teroidthe	erapy in the	past4			Yes		No	
weeks?  Is there documentation that Thyroid Eye Disease (TED) Clinical Activity Score (CAS) is ≥4?									.,			
is there documentation that I hyroid Eye Dis	ease (TED) (	Clinical A	ctivity Score	(CAS)is≥	:4'?				Yes		No	
Does member require immediate surgical	☐ Yes	□ No			or correctiv	re			Yes		No	
ophthalmological intervention?	<u> </u>		surge	y/irradia	tion?							
Is there documentation the member is:	-	□ Eut	thyroid									
	☐ Mildly hypo/hyper-thyroid with free thyroxine (FT4)											

Page 1 of 2 Effective: 06/07/2021 C20625-A 12-2021

					☐ Free triiodothyronine (FT3) levels less than 50% above or below normal limits						
Will Tepezza be used in combination with another biologic immunomodulator such as rituximab, Actemra, or Kevzara?		Yes	didor	No	Will a female of reproductive potential be using effective contraception prior to starting therapy, during treatment, and for 6 months following last dose of Tepezza?						
records.	ribin	g prov	naer	teels	is important to this review. Please specify below or submit medical						
Signature affirms that information given on this form is true and accurate and reflects office notes.											
Prescribing Provider's Signature	e:				Date:						

## Please note: Incomplete forms or forms without the chart notes will be returned

Office notes, labs, and medical testing relevant to the request that show medical justification are required.

Standard turnaround time is 24 hours. You can call to check the status of a request. Pennsylvania CHIP:1-800-822-2447.

Effective: 06/07/2021 C20625-A 12-2021